Employers Cut Coverage for Weight-Loss Drugs Amid Rising Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Coverage Reduction: According to The Wall Street Journal, employers like Cigna and PricewaterhouseCoopers are increasingly limiting or eliminating coverage for GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, reflecting growing concerns over rising healthcare costs.
- Employer Responses: New data reveals that 11% of large employers have either dropped or plan to drop coverage for GLP-1 medications, while over a quarter are tightening utilization controls, indicating heightened awareness of the financial implications of these drugs.
- Market Challenges: Despite strong demand for GLP-1 drugs, decisions by employers and insurers regarding coverage will significantly impact the future growth trajectory of the multibillion-dollar obesity drug market, particularly in balancing healthcare costs with employee benefits.
- Long-Term Cost Benefits: Some companies continue to advocate for broader coverage, arguing that GLP-1 medications may lower long-term healthcare costs by reducing obesity-related illnesses and hospitalizations, yet commercial insurance coverage for weight-loss use remains stagnant at around 50%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Employers Cut Coverage for Weight-Loss Drugs Amid Rising Costs
- Coverage Reduction: According to The Wall Street Journal, employers like Cigna and PricewaterhouseCoopers are increasingly limiting or eliminating coverage for GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, reflecting growing concerns over rising healthcare costs.
- Employer Responses: New data reveals that 11% of large employers have either dropped or plan to drop coverage for GLP-1 medications, while over a quarter are tightening utilization controls, indicating heightened awareness of the financial implications of these drugs.
- Market Challenges: Despite strong demand for GLP-1 drugs, decisions by employers and insurers regarding coverage will significantly impact the future growth trajectory of the multibillion-dollar obesity drug market, particularly in balancing healthcare costs with employee benefits.
- Long-Term Cost Benefits: Some companies continue to advocate for broader coverage, arguing that GLP-1 medications may lower long-term healthcare costs by reducing obesity-related illnesses and hospitalizations, yet commercial insurance coverage for weight-loss use remains stagnant at around 50%.
See More
Eli Lilly Reports Positive Results for Obesity Drug Retatrutide
- Significant Weight Loss: In the Phase 3 TRIUMPH-1 study, adults receiving the highest dose of retatrutide lost an average of 70.3 pounds (31.89 kg), or 28.3% of their body weight, demonstrating the drug's strong potential in the weight loss sector and positioning it as a potential blockbuster for Lilly in the obesity treatment market.
- Health Condition Improvements: The study revealed that retatrutide reduced breathing interruptions by up to 36.1 events per hour in patients with moderate-to-severe obstructive sleep apnea, representing a 61% improvement, while pain scores in knee osteoarthritis patients decreased by 73%, indicating the drug's effectiveness in addressing obesity-related health issues.
- Diabetes Control Effectiveness: In the TRANSCEND-T2D-1 study, retatrutide lowered A1C levels by up to 2 percentage points in type 2 diabetes patients, with 90% achieving an A1C below 7%, showcasing the drug's potential in diabetes management and its broader implications for patient health.
- Cardiovascular Risk Improvements: Across both studies, retatrutide improved several heart disease risk factors, including reductions in triglycerides and non-HDL cholesterol, along with lower blood pressure and waist circumference, enhancing the drug's market appeal and potential for widespread adoption.
See More
Eli Lilly Acquires Vaccine Firms to Diversify Business
- Significant Revenue Growth: Eli Lilly reported $12.8 billion in revenue for Q1 2026, with Mounjaro and Zepbound accounting for nearly two-thirds, showcasing strong market demand and the company's leadership in the GLP-1 weight-loss drug category with year-over-year sales growth of 125% and 80%, respectively.
- Strategic Acquisition Moves: The company is spending $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company, rapidly enhancing its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future market expansion.
- Forward-Looking Business Planning: Eli Lilly recognizes that the success of its GLP-1 drugs is not everlasting, thus this acquisition is a proactive measure to ensure competitiveness after patent protections expire, preparing for sustained growth in the long term.
- Industry Leadership Focus: Despite a high P/E ratio of 39, significantly above the pharmaceutical average of 24, Eli Lilly's management is committed to diversifying its portfolio and developing new GLP-1 drugs, aiming to solidify its leadership position and achieve long-term success in the pharmaceutical industry.
See More
Eli Lilly's $3.8 Billion Vaccine Investment
- Vaccine Investment Strategy: Eli Lilly's recent $3.8 billion acquisition of Curevo, LimmaTech Biologics AG, and Vaccine Company rapidly enhances its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future growth.
- GLP-1 Drug Performance: The GLP-1 weight-loss drugs Mounjaro and Zepbound achieved sales growth of 125% and 80% respectively in Q1 2026, collectively generating approximately $12.8 billion in revenue, demonstrating strong market demand and leadership position.
- Diversification Strategy: Recognizing that the success of GLP-1 drugs is not everlasting, Eli Lilly is strategically investing in vaccines to mitigate risks and ensure sustained business growth in the future, reflecting sound financial stewardship.
- Investor Focus: While value investors may be cautious about Eli Lilly's high P/E ratio of 39x, growth-oriented investors are likely to be attracted by the potential of its GLP-1 drugs and new drug developments, indicating the company's long-term growth potential in the pharmaceutical industry.
See More
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Employers Cut Coverage for Weight-Loss Drugs Amid Rising Costs
- Coverage Reduction: According to The Wall Street Journal, employers like Cigna and PricewaterhouseCoopers are increasingly limiting or eliminating coverage for GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, reflecting growing concerns over rising healthcare costs.
- Employer Responses: New data reveals that 11% of large employers have either dropped or plan to drop coverage for GLP-1 medications, while over a quarter are tightening utilization controls, indicating heightened awareness of the financial implications of these drugs.
- Market Challenges: Despite strong demand for GLP-1 drugs, decisions by employers and insurers regarding coverage will significantly impact the future growth trajectory of the multibillion-dollar obesity drug market, particularly in balancing healthcare costs with employee benefits.
- Long-Term Cost Benefits: Some companies continue to advocate for broader coverage, arguing that GLP-1 medications may lower long-term healthcare costs by reducing obesity-related illnesses and hospitalizations, yet commercial insurance coverage for weight-loss use remains stagnant at around 50%.
See More
Eli Lilly Reports Positive Results for Obesity Drug Retatrutide
- Significant Weight Loss: In the Phase 3 TRIUMPH-1 study, adults receiving the highest dose of retatrutide lost an average of 70.3 pounds (31.89 kg), or 28.3% of their body weight, demonstrating the drug's strong potential in the weight loss sector and positioning it as a potential blockbuster for Lilly in the obesity treatment market.
- Health Condition Improvements: The study revealed that retatrutide reduced breathing interruptions by up to 36.1 events per hour in patients with moderate-to-severe obstructive sleep apnea, representing a 61% improvement, while pain scores in knee osteoarthritis patients decreased by 73%, indicating the drug's effectiveness in addressing obesity-related health issues.
- Diabetes Control Effectiveness: In the TRANSCEND-T2D-1 study, retatrutide lowered A1C levels by up to 2 percentage points in type 2 diabetes patients, with 90% achieving an A1C below 7%, showcasing the drug's potential in diabetes management and its broader implications for patient health.
- Cardiovascular Risk Improvements: Across both studies, retatrutide improved several heart disease risk factors, including reductions in triglycerides and non-HDL cholesterol, along with lower blood pressure and waist circumference, enhancing the drug's market appeal and potential for widespread adoption.
See More
Eli Lilly Acquires Vaccine Firms to Diversify Business
- Significant Revenue Growth: Eli Lilly reported $12.8 billion in revenue for Q1 2026, with Mounjaro and Zepbound accounting for nearly two-thirds, showcasing strong market demand and the company's leadership in the GLP-1 weight-loss drug category with year-over-year sales growth of 125% and 80%, respectively.
- Strategic Acquisition Moves: The company is spending $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company, rapidly enhancing its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future market expansion.
- Forward-Looking Business Planning: Eli Lilly recognizes that the success of its GLP-1 drugs is not everlasting, thus this acquisition is a proactive measure to ensure competitiveness after patent protections expire, preparing for sustained growth in the long term.
- Industry Leadership Focus: Despite a high P/E ratio of 39, significantly above the pharmaceutical average of 24, Eli Lilly's management is committed to diversifying its portfolio and developing new GLP-1 drugs, aiming to solidify its leadership position and achieve long-term success in the pharmaceutical industry.
See More
Eli Lilly's $3.8 Billion Vaccine Investment
- Vaccine Investment Strategy: Eli Lilly's recent $3.8 billion acquisition of Curevo, LimmaTech Biologics AG, and Vaccine Company rapidly enhances its presence in the infectious disease sector, which, while having limited short-term impact, lays the groundwork for future growth.
- GLP-1 Drug Performance: The GLP-1 weight-loss drugs Mounjaro and Zepbound achieved sales growth of 125% and 80% respectively in Q1 2026, collectively generating approximately $12.8 billion in revenue, demonstrating strong market demand and leadership position.
- Diversification Strategy: Recognizing that the success of GLP-1 drugs is not everlasting, Eli Lilly is strategically investing in vaccines to mitigate risks and ensure sustained business growth in the future, reflecting sound financial stewardship.
- Investor Focus: While value investors may be cautious about Eli Lilly's high P/E ratio of 39x, growth-oriented investors are likely to be attracted by the potential of its GLP-1 drugs and new drug developments, indicating the company's long-term growth potential in the pharmaceutical industry.
See More
